STERIS plc (NYSE:STE) Director Jacqueline B. Kosecoff Sells 4,584 Shares

STERIS plc (NYSE:STEGet Free Report) Director Jacqueline B. Kosecoff sold 4,584 shares of the company’s stock in a transaction dated Monday, May 13th. The stock was sold at an average price of $231.53, for a total value of $1,061,333.52. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink.

STERIS Price Performance

NYSE STE traded down $0.54 during midday trading on Wednesday, hitting $235.46. The company had a trading volume of 690,052 shares, compared to its average volume of 486,301. The firm has a 50-day moving average price of $217.13 and a 200-day moving average price of $216.52. The company has a market capitalization of $23.27 billion, a PE ratio of 61.64 and a beta of 0.81. The company has a current ratio of 3.06, a quick ratio of 2.34 and a debt-to-equity ratio of 0.49. STERIS plc has a twelve month low of $195.47 and a twelve month high of $254.00.

STERIS (NYSE:STEGet Free Report) last announced its quarterly earnings data on Wednesday, May 8th. The medical equipment provider reported $2.58 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.41 by $0.17. STERIS had a net margin of 6.95% and a return on equity of 13.73%. The firm had revenue of $1.42 billion for the quarter, compared to the consensus estimate of $1.41 billion. During the same period in the prior year, the company posted $2.30 earnings per share. The business’s revenue for the quarter was up 10.8% on a year-over-year basis. As a group, analysts anticipate that STERIS plc will post 9.12 earnings per share for the current fiscal year.

STERIS Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, June 26th. Shareholders of record on Wednesday, June 12th will be issued a $0.52 dividend. This represents a $2.08 dividend on an annualized basis and a dividend yield of 0.88%. The ex-dividend date of this dividend is Wednesday, June 12th. STERIS’s dividend payout ratio is presently 54.45%.

Wall Street Analyst Weigh In

Several analysts recently issued reports on STE shares. TheStreet upgraded STERIS from a “c+” rating to a “b” rating in a report on Wednesday, February 7th. KeyCorp initiated coverage on STERIS in a research note on Tuesday, February 6th. They issued an “overweight” rating and a $253.00 price objective on the stock. Needham & Company LLC restated a “hold” rating on shares of STERIS in a research note on Friday, May 10th. Piper Sandler restated a “neutral” rating and issued a $225.00 price objective (up previously from $220.00) on shares of STERIS in a research note on Friday, May 10th. Finally, StockNews.com upgraded STERIS from a “hold” rating to a “buy” rating in a research note on Saturday. Three analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $241.60.

Check Out Our Latest Research Report on STERIS

Hedge Funds Weigh In On STERIS

A number of institutional investors have recently modified their holdings of STE. First Personal Financial Services bought a new position in STERIS in the first quarter valued at about $25,000. Millburn Ridgefield Corp acquired a new position in STERIS during the 3rd quarter worth approximately $25,000. Catalyst Capital Advisors LLC bought a new position in STERIS in the 3rd quarter valued at approximately $25,000. J.Safra Asset Management Corp boosted its holdings in shares of STERIS by 77.9% during the 1st quarter. J.Safra Asset Management Corp now owns 121 shares of the medical equipment provider’s stock valued at $27,000 after acquiring an additional 53 shares in the last quarter. Finally, Quent Capital LLC grew its position in STERIS by 112.7% during the 1st quarter. Quent Capital LLC now owns 134 shares of the medical equipment provider’s stock worth $30,000 after acquiring an additional 71 shares during the last quarter. Institutional investors and hedge funds own 94.69% of the company’s stock.

STERIS Company Profile

(Get Free Report)

STERIS plc provides infection prevention products and services worldwide. It operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; endoscopy accessories, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services.

See Also

Receive News & Ratings for STERIS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for STERIS and related companies with MarketBeat.com's FREE daily email newsletter.